Lueurs et leurres de la santé globale À propos de MenAfriVac®, un vaccin « africain » contre la méningite

Abstract

In biomedical narratives, the Meningitis Vaccine Project (MVP) enabled the technology transfer for the development and implementation of MenAfriVac® vaccine at an affordable price for African countries. The presentation of MVP as a success story, however, may be more sociotechnical myth than fact. MenAfriVac® is far from being a silver bullet . While successful in eliminating Meningitis A, MVP rhetoric highlighting meningitis control obscured a more complex epidemiological context. This paper analyzes the discursive construction of success that supports global health single vaccine initiatives.